Medpace Holdings Inc vs Sezzle Inc — how do they compare? Medpace Holdings Inc trades at $523 (market cap $15.18B), while Sezzle Inc trades at $173.97 (market cap $6.03B). The key difference: Medpace Holdings Inc is far larger — about 2.5× Sezzle Inc's market cap, and Sezzle Inc is trading nearer its 52-week high, Medpace Holdings Inc nearer its low. Which is the better fit depends on your goals.
| MEDP | SEZL | |
|---|---|---|
Market Cap | $15.18B | $6.03B |
Sector | Technology | Technology |
52-Week High | $620.59 | $188.55 |
52-Week Low | $393.42 | $50.97 |
Enterprise Value | $14.65B | $6.06B |
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $527.93, down 1.82% on the day, with a neutral technical signal and mixed oscillators. The stock shows strong profitability with a 17.19% net margin and 77.25% ROE, though valuations are elevated with a P/E of 33.22. Recent quarters have consistently beaten EPS estimates, but a class action lawsuit filed in June 2026 adds uncertainty. Revenue is projected to grow to $2.7B in 2026, while cash flow trends improve from negative to positive net cash flow.
The outlook is cautious due to high valuation and legal overhangs, but fundamental strength in earnings and backlog quality provides support. Analyst consensus is mixed with a $497 price target below current levels, indicating limited near-term upside. Key risks include lawsuit outcomes and competitive pressures in the CRO sector.
Sezzle Inc. (SEZL) trades at $171.76, down 1.67% today, with a bullish technical signal from moving averages and a neutral RSI near 50. The stock shows strong fundamental momentum, with Q1 2026 EPS of $1.43 beating estimates of $1.24, and robust profitability metrics including a 30.83% net income margin and 91.95% ROE. Recent news highlights subscriber growth of 48.4% year-over-year and product expansions, supporting the positive sentiment.
Outlook remains favorable due to consistent earnings beats and raised guidance, but risks include high valuation multiples (P/E of 41) and competitive pressures in the BNPL sector. Analyst consensus is a Moderate Buy with a $162 price target, suggesting potential downside from current levels, though the high target of $190 indicates upside if growth persists.
Trailing returns across standard periods
Latest headlines on both assets
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →Sezzle Inc is a financial technology company that operates a Buy Now, Pay Later (BNPL) payment platform. The company allows consumers to make purchases and split the total cost into four interest-free payments over six weeks, primarily serving the e-commerce retail market. Sezzle focuses on promoting financial empowerment by offering a transparent and responsible payment solution to customers at the point of sale.
Read more on SEZL →